Friday, November 24th, 2017, London, UK: The Biogerontology Research Foundation is pleased to announce that its Managing Trustee, Dmitry Kaminskiy, will be giving a keynote presentation at the Digital Healthcare World Congress on November 30th, 2017, in London, UK, where he will be presenting on the topic of “How AI and Blockchain Will Take Drug Discovery to the Next Level”. The conference will run from November 29th-30th, 2017, at the Kensington Conference and Events Centre in London, UK.
“Blockchain technologies are rapidly decentralizing and democratizing many different fields, industries and applications. Meanwhile, AI, and in particular deep-learning based approaches, have now become famous for its similarly disruptive potential. The next big field and industry to be transformed by the synergistic convergence of these two progress-galvanizing powerhouses is healthcare, and in particular the clinical translation and validation of therapies aiming to extend healthy, productive longevity” said Dmitry Kaminskiy, Managing Trustee of the Biogerontology Research Foundation.
Since its inception nearly a decade ago, the Biogerontology Research Foundation has strove to apply synergistic, cross-disciplinary approaches to the problem of biological aging and the looming timebomb of demographic aging, and to focus on approaches that aren’t being explored by other ageing research foundations and institutions, taking mature science and technology that have proven themselves in other industries and applying them to the task of extending healthy longevity. Much of the foundation’s past research efforts have focused on the application of AI and deep learning to ageing research, and the topic of blockchain technologies have already begun to become a feature of our ongoing research efforts, as evidenced by the recent publication of a paper titled “Converging blockchain and next-generation artificial intelligence technologies to decentralize and accelerate biomedical research and healthcare” in the journal Oncotarget by Biogerontology Research Foundation Chief Science Officer Alex Zhavoronkov, among others.